Enzo Biochem Inc
Welcome to a Medical Battery specialist of the Agilent Battery
Apart from detailing the Company's success in monetizing its intellectual property estate, Mr. Weiner also discussed at length Enzo's strategic plan for molecular diagnostics, which he termed 'very exciting and promising.'
Specifically, Mr. Weiner said Enzo is poised to deliver products and services that are high performing, cost-effective and easily adaptable to today's molecular marketplace, in which clinical labs both nationwide and globally are facing margin pressures despite growth in demand.
'While the industry is over $5 billion today and growing with battery such as Agilent N9912A Battery, Agilent N9915A Battery, Agilent N9916A Battery, Agilent N9917A Battery, Agilent N9927A Battery, Agilent N9937A Battery, Anritsu MT9082A2 Battery, Anritsu MT9082A8 Battery, Anritsu MT9082C9 Battery, Anritsu MT9082A2 Battery, Anritsu MT9080 Battery, Anritsu MT9080D Battery, with this growth have come unprecedented challenges to the clinical laboratories in the form of margin pressure as increased costs are being met by decreased reimbursements for their services,' said Mr. Weiner.
'To meet this need, our uniquely integrated structure has enabled us to develop high-performing molecular diagnostic products and services, at savings to the marketplace of 30% to 50%, while providing easily adaptable solutions that will allow labs to utilize them with little or no change to their normal workflow. '
He noted the recent approval by the New York State's Department of Health of the AmpiProbe HCV™ test as just the start of a battery of assays under development geared to molecular diagnostics. Mr. Weiner commented: 'We are highly encouraged by the response to news of this new assay, and we are making significant progress. We are looking forward to further assay validations for our AmpiProbe™ platform with a pipeline encompassing a number of products, including a panel addressing the women's health market as well as other infectious diseases. Other platforms that we have developed are expected to yield products in the fields of cancer, immunology and cardiology, to name a few.'
Shareholders were reminded that today's announced settlement with Agilent impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, eight of which remain pending.
Mr. Weiner noted that over the past five years, Enzo has received more than $65 million in settlements and licensing revenues, well in excess of the Company's total legal spending in the same period.
Shareholders at the meeting overwhelmingly approved the re-election of the Company's nominees, Gregory M. Bortz and Dov Perlysky, as Class I directors to hold office for a term of three years.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company's Form 10-K for the fiscal year ended July 31, 2015. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
Saturday, January 9, 2016
Tektronix Unveils Cost-Effective
Tektronix Unveils Cost-Effective
Welcome to a Medical Battery specialist of the Tektronix Battery
Tektronix, Inc., a leading worldwide provider of test, measurement and monitoring instrumentation, today announced the industry's first graphical touchscreen Electrochemistry Lab Systems, the 2450-EC and 2460-EC. These new Keithley interactive solutions offer a lower cost, more flexible, and easier method for conducting a range of electrochemistry experiments, including cyclic voltammetry, chronoamperometry, and chronopotentiometry. For more information, go to: http://www.tek.com/electrochemistry-lab-systems
The traditional approach to electrochemistry testing involves potentiostat instrumentation and vendor-supplied software that is typically not customizable. The Keithley solutions bring a number of advantages, including a lower purchase price and cost of ownership with battery like Tektronix Y350C Battery, Tektronix Y400 Battery, Rohde Schwarz FSH626 Battery, Rohde Schwarz FSH-Z32 Battery, Rohde Schwarz FSH6 Battery, Rohde Schwarz FSH18 Battery, Rohde Schwarz FSH3 Battery, Biocare ECG-9803G Battery, Biocare HYLB-114A Battery, Aspect 185-0152 Battery, Aspect 186-0208 Battery, Aspect VTI 14564 Battery, customizable software, and simple operation with the ability to run experiments, make measurements, and generate voltammogram plot results directly on the instruments' touchscreen display. With gestural 'pinch and zoom' on the graphical display, users can quickly analyze the results and make quick research and design decisions. Potentiostats lack front panel controls and require a separate PC to set up and run experiments.
"Students, professors, and researchers are influenced by the user interfaces used on their smart phones and expect the same from their instrumentation," said Mike Flaherty, general manager, Keithley product line at Tektronix. "The 2450-EC and 2460-EC embrace these concepts to bring exceptional ease of use to electrochemistry, minimizing the instrument learning curve, and enabling customers to learn faster, work smarter, and invent easier."
Electrochemists, chemists, and other scientists use electrical measurement techniques to study chemical reactions and dynamics. Keithley's Electrochemistry Lab Systems are versatile instruments that can source and measure voltage or current and can be used to compare results to parameters for voltammetry experiments or over time for chronoamperometry experiments. These instruments are 4-quadrant instruments that can both source power and sink power. Typical potentiostats are 2-quadrant, which limits their use as a general purpose instrument beyond electrochemistry applications. In contrast the 2450-EC and 2460-EC can be repurposed as a general use lab tool for such applications as I-V testing, leakage testing, and battery charge/discharge profiling.
Chemistry and electrochemistry researchers are pushing the limits of what's possible with the pre-programmed, non-modifiable tests furnished with most potentiostats. In contrast, the 2450-EC and 2460-EC provide nearly limitless flexibility through the use of an embedded open-source Test Script Processor (TSP®) system that enables researchers to create their own library of electrochemistry test scripts that can be modified as tests and measurements evolve.
The 2450-EC and 2460-EC are housed in a compact package that enables easy transport around a lab, without the need for a cart to transport a much larger potentiostat and computer. The 2450-EC can source and measure up to 200V or 1 amp, with source/sink power up to 22 watts; the 2460-EC can source and measure up to 100V or 7amp, with source/sink power up to 100 watts. These instruments offer excellent measurement sensitivity - as low as 10nV and 10fA, source and measure ranges as low as 20mV and 10nA, and 0.012% basic measurement accuracy with 6.5 digit resolution. Each instrument features a high-resolution five inch touchscreen display for intuitive usage and minimized learning curve.
Welcome to a Medical Battery specialist of the Tektronix Battery
Tektronix, Inc., a leading worldwide provider of test, measurement and monitoring instrumentation, today announced the industry's first graphical touchscreen Electrochemistry Lab Systems, the 2450-EC and 2460-EC. These new Keithley interactive solutions offer a lower cost, more flexible, and easier method for conducting a range of electrochemistry experiments, including cyclic voltammetry, chronoamperometry, and chronopotentiometry. For more information, go to: http://www.tek.com/electrochemistry-lab-systems
The traditional approach to electrochemistry testing involves potentiostat instrumentation and vendor-supplied software that is typically not customizable. The Keithley solutions bring a number of advantages, including a lower purchase price and cost of ownership with battery like Tektronix Y350C Battery, Tektronix Y400 Battery, Rohde Schwarz FSH626 Battery, Rohde Schwarz FSH-Z32 Battery, Rohde Schwarz FSH6 Battery, Rohde Schwarz FSH18 Battery, Rohde Schwarz FSH3 Battery, Biocare ECG-9803G Battery, Biocare HYLB-114A Battery, Aspect 185-0152 Battery, Aspect 186-0208 Battery, Aspect VTI 14564 Battery, customizable software, and simple operation with the ability to run experiments, make measurements, and generate voltammogram plot results directly on the instruments' touchscreen display. With gestural 'pinch and zoom' on the graphical display, users can quickly analyze the results and make quick research and design decisions. Potentiostats lack front panel controls and require a separate PC to set up and run experiments.
"Students, professors, and researchers are influenced by the user interfaces used on their smart phones and expect the same from their instrumentation," said Mike Flaherty, general manager, Keithley product line at Tektronix. "The 2450-EC and 2460-EC embrace these concepts to bring exceptional ease of use to electrochemistry, minimizing the instrument learning curve, and enabling customers to learn faster, work smarter, and invent easier."
Electrochemists, chemists, and other scientists use electrical measurement techniques to study chemical reactions and dynamics. Keithley's Electrochemistry Lab Systems are versatile instruments that can source and measure voltage or current and can be used to compare results to parameters for voltammetry experiments or over time for chronoamperometry experiments. These instruments are 4-quadrant instruments that can both source power and sink power. Typical potentiostats are 2-quadrant, which limits their use as a general purpose instrument beyond electrochemistry applications. In contrast the 2450-EC and 2460-EC can be repurposed as a general use lab tool for such applications as I-V testing, leakage testing, and battery charge/discharge profiling.
Chemistry and electrochemistry researchers are pushing the limits of what's possible with the pre-programmed, non-modifiable tests furnished with most potentiostats. In contrast, the 2450-EC and 2460-EC provide nearly limitless flexibility through the use of an embedded open-source Test Script Processor (TSP®) system that enables researchers to create their own library of electrochemistry test scripts that can be modified as tests and measurements evolve.
The 2450-EC and 2460-EC are housed in a compact package that enables easy transport around a lab, without the need for a cart to transport a much larger potentiostat and computer. The 2450-EC can source and measure up to 200V or 1 amp, with source/sink power up to 22 watts; the 2460-EC can source and measure up to 100V or 7amp, with source/sink power up to 100 watts. These instruments offer excellent measurement sensitivity - as low as 10nV and 10fA, source and measure ranges as low as 20mV and 10nA, and 0.012% basic measurement accuracy with 6.5 digit resolution. Each instrument features a high-resolution five inch touchscreen display for intuitive usage and minimized learning curve.
Friday, January 8, 2016
LifeProof brings its FRĒ Power waterproof battery
LifeProof brings its FRĒ Power waterproof battery
Welcome to a Medical Battery specialist of the Aspect Battery
LifeProof today has announced the expansion of its FRĒ Power iPhone case to the iPhone 6/s Plus. The FRĒ Power case combines the classic waterproof design of LifeProof’s cases with a battery pack, creating one of the most versatile cases on the market.
The FRĒ Power case is IP68 certified, meaning it can be submerged in 2 meters of water for up to an hour. It’s also rated for protection against dirt, snow, dust, and accidental drops. LifeProof says the case can withstand a drop from as high as 6.6 feet. It’s worth noting that since this case is part of the FRĒ lineup, it does offer a built-in screen protector to protect it from scratches and scuffs on the display.
As for the battery with like Aspect BIS Vista Battery, Edanins ECG-12A Battery, Edanins HYHB-1188 Battery, Fukuda BTE-001 Battery, Fukuda FX-8222 Battery, Mindray LI13I001A Battery, Mindray IMEC8 Battery, Mindray IMEC10 Battery, Mindray IPM12 Battery, Mindray IEMEC12 Battery, Philips VM1 Battery, Philips VSI Batteryaspect of the FRĒ Power, it packs a 3,200mAh pack that is capable of charging the iPhone in its entirety once. LifeProof touts that the FRĒ Power case features Rapid Recharge, which quickly recharges the iPhone 6s Plus and the case itself, as well as Auto Stop Charge for turning the case off when the iPhone reaches a full charge.
While a specific release date is still unclear, LifeProof’s website lists the FRĒ Power as coming soon. It is slated to be available in “Blacktop Black” and “Base Jump Blue” for $149.99.
LIFEPROOF ANNOUNCES FIRST WATERPROOF BATTERY CASE FOR PLUS-SIZED IPHONES– IPHONE 6 PLUS AND IPHONE 6S PLUS CHARGE AHEAD WITH FRE POWER AT CES 2016 –
LAS VEGAS, Jan. 5, 2016 /PRNEWSWIRE/ — LifeProof smartphone cases defy expectations by taking handheld technology on remarkable adventures. Today, LifeProof, the No. 1 selling waterproof case in the U.S., introduces FRĒ Power for iPhone 6s Plus, the first waterproof battery case for a plus-sized iPhone.
LifeProof, the No. 1-most trusted waterproof case brand announces FRE Power for iPhone 6s Plus, the first waterproof battery case for a plus-sized iPhone.
This exciting new product is debuting at CES 2016 and is compatible with iPhone 6 Plus.
“LifeProof continues to defy the limits of possibility with smartphones,” said LifeProof President and CEO Pete Lindgren. “FRĒ Power for iPhone 6s Plus takes Apple’s large form-factor device on bigger, better adventures with double the battery capacity and our award-winning four-proof protection against the elements.”
Welcome to a Medical Battery specialist of the Aspect Battery
LifeProof today has announced the expansion of its FRĒ Power iPhone case to the iPhone 6/s Plus. The FRĒ Power case combines the classic waterproof design of LifeProof’s cases with a battery pack, creating one of the most versatile cases on the market.
The FRĒ Power case is IP68 certified, meaning it can be submerged in 2 meters of water for up to an hour. It’s also rated for protection against dirt, snow, dust, and accidental drops. LifeProof says the case can withstand a drop from as high as 6.6 feet. It’s worth noting that since this case is part of the FRĒ lineup, it does offer a built-in screen protector to protect it from scratches and scuffs on the display.
As for the battery with like Aspect BIS Vista Battery, Edanins ECG-12A Battery, Edanins HYHB-1188 Battery, Fukuda BTE-001 Battery, Fukuda FX-8222 Battery, Mindray LI13I001A Battery, Mindray IMEC8 Battery, Mindray IMEC10 Battery, Mindray IPM12 Battery, Mindray IEMEC12 Battery, Philips VM1 Battery, Philips VSI Batteryaspect of the FRĒ Power, it packs a 3,200mAh pack that is capable of charging the iPhone in its entirety once. LifeProof touts that the FRĒ Power case features Rapid Recharge, which quickly recharges the iPhone 6s Plus and the case itself, as well as Auto Stop Charge for turning the case off when the iPhone reaches a full charge.
While a specific release date is still unclear, LifeProof’s website lists the FRĒ Power as coming soon. It is slated to be available in “Blacktop Black” and “Base Jump Blue” for $149.99.
LIFEPROOF ANNOUNCES FIRST WATERPROOF BATTERY CASE FOR PLUS-SIZED IPHONES– IPHONE 6 PLUS AND IPHONE 6S PLUS CHARGE AHEAD WITH FRE POWER AT CES 2016 –
LAS VEGAS, Jan. 5, 2016 /PRNEWSWIRE/ — LifeProof smartphone cases defy expectations by taking handheld technology on remarkable adventures. Today, LifeProof, the No. 1 selling waterproof case in the U.S., introduces FRĒ Power for iPhone 6s Plus, the first waterproof battery case for a plus-sized iPhone.
LifeProof, the No. 1-most trusted waterproof case brand announces FRE Power for iPhone 6s Plus, the first waterproof battery case for a plus-sized iPhone.
This exciting new product is debuting at CES 2016 and is compatible with iPhone 6 Plus.
“LifeProof continues to defy the limits of possibility with smartphones,” said LifeProof President and CEO Pete Lindgren. “FRĒ Power for iPhone 6s Plus takes Apple’s large form-factor device on bigger, better adventures with double the battery capacity and our award-winning four-proof protection against the elements.”
V377 to release with 5,000 mAh battery
V377 to release with 5,000 mAh battery
Welcome to a Medical Battery specialist of the Philips Battery
Philips launches a steady flow of smartphones and another one is about to arrive. The Philips Xenium V377 is to release with a sizeable 5000 mAh battery and that will be major highlight of the new phone. Other specs are not so impressive, but for those looking for good battery life and a competitive price it could be a good choice.
The Philips Xenium V377 specifications include a 1.3GHz MediaTek MT6580 quad-core processor and a 5-inch display with resolution of 1280 x 720 (HD). It has 1GB of RAM, 8GB of internal storage (expandable via microSD), and connectivity includes 3G with battery such as Philips VS2+ Battery, Philips 863266 Battery, Philips 989803166291 Battery, Welch Allyn 4500-84 Battery, Welch Allyn 450EO Battery, Welch Allyn 450TO Battery, Welch Allyn 45MTO Battery, Welch Allyn 45NTO Battery, Kaden Yasen WP-YHD-3160 Battery, Kaden Yasen ECG-901 Battery, Kaden Yasen HYHB-1270 Battery(sadly no 4G LTE), WiFi, Bluetooth 4.0, GPS, and microUSB 2.0.
This new Philips phone has an 8-megapixel rear camera featuring autofocus and LED flash, as well as a 2-megapixel front-facing snapper. It’s a dual SIM handset running the Android 5.1 Lollipop OS skinned with the company’s own UI, and features Miracast support. The handset is 10.9mm thick, weighing in at 188.5g.
Power users will appreciate the 5000 mAh battery claimed to offer standby time of up to a month or up to 29 hours of talk time. Philips further claims that a single full charge will enable the play of 3,150 audio songs, and that’s some going. If you need to extend the battery life there’s a physical button on the left of the handset to switch to a power saving mode.
The Philips Xenium V377 is scheduled to launch in Russia by the end of the month, but there’s no news yet on availability for other regions. The price for Russia is 8990 rubles and that’s equivalent to around $130, £85, €120, or Rs, 8650, although pricing may vary according to market.
What are your first thoughts on the Philips Xenium V377? Does this sound like a smartphone you might buy if it launches in your region? It’s always good to hear from readers so why not let us know.
Welcome to a Medical Battery specialist of the Philips Battery
Philips launches a steady flow of smartphones and another one is about to arrive. The Philips Xenium V377 is to release with a sizeable 5000 mAh battery and that will be major highlight of the new phone. Other specs are not so impressive, but for those looking for good battery life and a competitive price it could be a good choice.
The Philips Xenium V377 specifications include a 1.3GHz MediaTek MT6580 quad-core processor and a 5-inch display with resolution of 1280 x 720 (HD). It has 1GB of RAM, 8GB of internal storage (expandable via microSD), and connectivity includes 3G with battery such as Philips VS2+ Battery, Philips 863266 Battery, Philips 989803166291 Battery, Welch Allyn 4500-84 Battery, Welch Allyn 450EO Battery, Welch Allyn 450TO Battery, Welch Allyn 45MTO Battery, Welch Allyn 45NTO Battery, Kaden Yasen WP-YHD-3160 Battery, Kaden Yasen ECG-901 Battery, Kaden Yasen HYHB-1270 Battery(sadly no 4G LTE), WiFi, Bluetooth 4.0, GPS, and microUSB 2.0.
This new Philips phone has an 8-megapixel rear camera featuring autofocus and LED flash, as well as a 2-megapixel front-facing snapper. It’s a dual SIM handset running the Android 5.1 Lollipop OS skinned with the company’s own UI, and features Miracast support. The handset is 10.9mm thick, weighing in at 188.5g.
Power users will appreciate the 5000 mAh battery claimed to offer standby time of up to a month or up to 29 hours of talk time. Philips further claims that a single full charge will enable the play of 3,150 audio songs, and that’s some going. If you need to extend the battery life there’s a physical button on the left of the handset to switch to a power saving mode.
The Philips Xenium V377 is scheduled to launch in Russia by the end of the month, but there’s no news yet on availability for other regions. The price for Russia is 8990 rubles and that’s equivalent to around $130, £85, €120, or Rs, 8650, although pricing may vary according to market.
What are your first thoughts on the Philips Xenium V377? Does this sound like a smartphone you might buy if it launches in your region? It’s always good to hear from readers so why not let us know.
V377 to release with 5,000 mAh battery
V377 to release with 5,000 mAh battery
Welcome to a Medical Battery specialist of the Philips Battery
Philips launches a steady flow of smartphones and another one is about to arrive. The Philips Xenium V377 is to release with a sizeable 5000 mAh battery and that will be major highlight of the new phone. Other specs are not so impressive, but for those looking for good battery life and a competitive price it could be a good choice.
The Philips Xenium V377 specifications include a 1.3GHz MediaTek MT6580 quad-core processor and a 5-inch display with resolution of 1280 x 720 (HD). It has 1GB of RAM, 8GB of internal storage (expandable via microSD), and connectivity includes 3G with battery such as Philips VS2+ Battery, Philips 863266 Battery, Philips 989803166291 Battery, Welch Allyn 4500-84 Battery, Welch Allyn 450EO Battery, Welch Allyn 450TO Battery, Welch Allyn 45MTO Battery, Welch Allyn 45NTO Battery, Kaden Yasen WP-YHD-3160 Battery, Kaden Yasen ECG-901 Battery, Kaden Yasen HYHB-1270 Battery(sadly no 4G LTE), WiFi, Bluetooth 4.0, GPS, and microUSB 2.0.
This new Philips phone has an 8-megapixel rear camera featuring autofocus and LED flash, as well as a 2-megapixel front-facing snapper. It’s a dual SIM handset running the Android 5.1 Lollipop OS skinned with the company’s own UI, and features Miracast support. The handset is 10.9mm thick, weighing in at 188.5g.
Power users will appreciate the 5000 mAh battery claimed to offer standby time of up to a month or up to 29 hours of talk time. Philips further claims that a single full charge will enable the play of 3,150 audio songs, and that’s some going. If you need to extend the battery life there’s a physical button on the left of the handset to switch to a power saving mode.
The Philips Xenium V377 is scheduled to launch in Russia by the end of the month, but there’s no news yet on availability for other regions. The price for Russia is 8990 rubles and that’s equivalent to around $130, £85, €120, or Rs, 8650, although pricing may vary according to market.
What are your first thoughts on the Philips Xenium V377? Does this sound like a smartphone you might buy if it launches in your region? It’s always good to hear from readers so why not let us know.
Welcome to a Medical Battery specialist of the Philips Battery
Philips launches a steady flow of smartphones and another one is about to arrive. The Philips Xenium V377 is to release with a sizeable 5000 mAh battery and that will be major highlight of the new phone. Other specs are not so impressive, but for those looking for good battery life and a competitive price it could be a good choice.
The Philips Xenium V377 specifications include a 1.3GHz MediaTek MT6580 quad-core processor and a 5-inch display with resolution of 1280 x 720 (HD). It has 1GB of RAM, 8GB of internal storage (expandable via microSD), and connectivity includes 3G with battery such as Philips VS2+ Battery, Philips 863266 Battery, Philips 989803166291 Battery, Welch Allyn 4500-84 Battery, Welch Allyn 450EO Battery, Welch Allyn 450TO Battery, Welch Allyn 45MTO Battery, Welch Allyn 45NTO Battery, Kaden Yasen WP-YHD-3160 Battery, Kaden Yasen ECG-901 Battery, Kaden Yasen HYHB-1270 Battery(sadly no 4G LTE), WiFi, Bluetooth 4.0, GPS, and microUSB 2.0.
This new Philips phone has an 8-megapixel rear camera featuring autofocus and LED flash, as well as a 2-megapixel front-facing snapper. It’s a dual SIM handset running the Android 5.1 Lollipop OS skinned with the company’s own UI, and features Miracast support. The handset is 10.9mm thick, weighing in at 188.5g.
Power users will appreciate the 5000 mAh battery claimed to offer standby time of up to a month or up to 29 hours of talk time. Philips further claims that a single full charge will enable the play of 3,150 audio songs, and that’s some going. If you need to extend the battery life there’s a physical button on the left of the handset to switch to a power saving mode.
The Philips Xenium V377 is scheduled to launch in Russia by the end of the month, but there’s no news yet on availability for other regions. The price for Russia is 8990 rubles and that’s equivalent to around $130, £85, €120, or Rs, 8650, although pricing may vary according to market.
What are your first thoughts on the Philips Xenium V377? Does this sound like a smartphone you might buy if it launches in your region? It’s always good to hear from readers so why not let us know.
Thursday, January 7, 2016
Stumps Obama and Stuns Retirees.
Stumps Obama and Stuns Retirees.
Welcome to a Medical Battery specialist of the Mindray Battery
These quotes heralded his efforts to create the so-called "socialist market economy" of China as clearly the economic model under Mao had failed to deliver the economic progress the country wanted. Deng's pioneering efforts unleashed the Chinese economy, generating decades of doubledigit growth that has now catapulted China to being the largest economy in the world. This dramatic growth has spurred the rise of giant corporations like Lenovo, Haier, Huawei, Mindray, TCL, BYD, and many others in a span of a couple of decades.
What can Indian businesses learn from the Chinese experience? Taking Deng's comments to heart, Chinese companies have experimented. Consider BYD. It started as a maker of nickel cadmium batteries with like Mindray D3 Battery, Mindray LI24I001A Battery, Mindray D6 Battery, Mindray LI34I001A Battery, Agilent N2910AM Battery, Agilent N3900 Battery, Agilent N3985A Battery, Philips ME202H Battery, Li202S-60A Battery, Li202S-66C Battery, Li202S Battery, Agilent N3993A Batteryin the mid-90s. Its founder, Wang Chuanfu, saw a market opportunity to make lithium ion batteries.
While the market opportunity existed, the cost of a manufacturing line for lithium ion batteries was well beyond the means of BYD, with a paid up capital of US$250,000, as the cost of a single manufacturing line was more than US$5 million due to the need for a clean room to avoid contaminants getting in to the battery during the manufacturing process—contaminants are the cause of lithium ion batteries exploding.
Undaunted, Wang Chuanfu innovated, creating the clean box, which cost next to nothing compared to a clean room, was modular, and scalable. The innovation essentially converted a fixed cost to a variable cost, making it possible for BYD to take advantage of the market opportunity it had spotted.
Importantly, the innovation also increased productivity because time was not spent suiting up to work in a clean room, bringing cost of manufacture down further. The result is that today BYD is the world's largest producer of batteries and has a commanding 25 per cent market share in mobile phone batteries. The willingness to experiment with new ideas and learn from it is a hallmark of many Chinese companies and something that Indian companies could more broadly adopt.
A second striking aspect of Chinese companies, and one that is distinct from the path taken by Indian companies, is the focus on the "common person" in second and third tier towns, rather than the urban middle class (really the upper classes) that has been the mainstay for Indian companies.
Consider for example Mindray, a leading maker of medical diagnostic equipment in China. Mindray focused on second and third tier hospitals and clinics in smaller towns. By doing so, it was able to bypass the global majors in their industry like GE, Siemens, Philips, and Toshiba, and build a strong branded business by selling comparable quality equipment at around 30 per cent lower prices.
The result of the first mover advantage has been that Mindray has become the brand of choice in the segments they target, as it has proven its quality and at price points that are difficult for the global majors to achieve.
Welcome to a Medical Battery specialist of the Mindray Battery
These quotes heralded his efforts to create the so-called "socialist market economy" of China as clearly the economic model under Mao had failed to deliver the economic progress the country wanted. Deng's pioneering efforts unleashed the Chinese economy, generating decades of doubledigit growth that has now catapulted China to being the largest economy in the world. This dramatic growth has spurred the rise of giant corporations like Lenovo, Haier, Huawei, Mindray, TCL, BYD, and many others in a span of a couple of decades.
What can Indian businesses learn from the Chinese experience? Taking Deng's comments to heart, Chinese companies have experimented. Consider BYD. It started as a maker of nickel cadmium batteries with like Mindray D3 Battery, Mindray LI24I001A Battery, Mindray D6 Battery, Mindray LI34I001A Battery, Agilent N2910AM Battery, Agilent N3900 Battery, Agilent N3985A Battery, Philips ME202H Battery, Li202S-60A Battery, Li202S-66C Battery, Li202S Battery, Agilent N3993A Batteryin the mid-90s. Its founder, Wang Chuanfu, saw a market opportunity to make lithium ion batteries.
While the market opportunity existed, the cost of a manufacturing line for lithium ion batteries was well beyond the means of BYD, with a paid up capital of US$250,000, as the cost of a single manufacturing line was more than US$5 million due to the need for a clean room to avoid contaminants getting in to the battery during the manufacturing process—contaminants are the cause of lithium ion batteries exploding.
Undaunted, Wang Chuanfu innovated, creating the clean box, which cost next to nothing compared to a clean room, was modular, and scalable. The innovation essentially converted a fixed cost to a variable cost, making it possible for BYD to take advantage of the market opportunity it had spotted.
Importantly, the innovation also increased productivity because time was not spent suiting up to work in a clean room, bringing cost of manufacture down further. The result is that today BYD is the world's largest producer of batteries and has a commanding 25 per cent market share in mobile phone batteries. The willingness to experiment with new ideas and learn from it is a hallmark of many Chinese companies and something that Indian companies could more broadly adopt.
A second striking aspect of Chinese companies, and one that is distinct from the path taken by Indian companies, is the focus on the "common person" in second and third tier towns, rather than the urban middle class (really the upper classes) that has been the mainstay for Indian companies.
Consider for example Mindray, a leading maker of medical diagnostic equipment in China. Mindray focused on second and third tier hospitals and clinics in smaller towns. By doing so, it was able to bypass the global majors in their industry like GE, Siemens, Philips, and Toshiba, and build a strong branded business by selling comparable quality equipment at around 30 per cent lower prices.
The result of the first mover advantage has been that Mindray has become the brand of choice in the segments they target, as it has proven its quality and at price points that are difficult for the global majors to achieve.
Venture Capital Dispatch
Venture Capital Dispatch
Welcome to a Medical Battery specialist of the Fluke Battery
Guardant Health Inc. has collected nearly $100 million to expand a service using genomic sequencing to help identify the best therapies for individual patients, Brian Gormley reports for Dow Jones VentureWire. The funding comes amid a push to use genetics to enable personalized cancer treatments. Guardant sequences DNA that tumor cells release into the blood. This can lead oncologists to select a genetically targeted therapy that is likely to work for a particular patient with advanced cancer. OrbiMed Advisors led the Series D round, which adds to the nearly $100 million Guardant raised previously. Existing backers Formation 8, Heritage Group, Khosla Ventures, Lightspeed Venture Partners, Pejman Mar and Sequoia Capital also participated.
Sisense Inc. has raised $50 million for technology that speeds and simplifies the analysis of large, complex data sets so that businesses can make faster decisions. The Series D round was led by Bessemer Venture Partners and included Battery with such as Fluke TiXB Battery, Fluke Ti9 Battery, Fluke TiRX Battery, Fluke TiS Battery, Fluke 215C Battery, Fluke 19XC Battery, Fluke 2X5C Battery, Fluke 435 Battery, Fluke 225C Battery, Contec ECG-1200 Battery, Edan SE-1200 Battery, Contec ECG-1200 BatteryVentures, Draper Fisher Jurvetson, Genesis Partners and Opus Capital.
Sierra Ventures has closed a $170 million fund. San Mateo, Calif.-based Sierra, which made its name with early bets on Intuit INTU -1.61%and Teradata, said it would use the funds to invest in early-stage consumer and enterprise software, as well as connected devices.
C4 Therapeutics Inc. has launched with $73 million in Series A financing and a plan to use a “shock and awe” approach to battling proteins involved in cancer and other diseases. Cobro Ventures led the Series A round, which also included Cormorant Asset Management, EG Capital Group, Kraft Group, Novartis AGNOVN.VX -1.28% and Roche Holding Ltd.
Flatiron Health Inc. has raised $175 million more from corporate and financial investors to expand a cloud-based platform designed to improve cancer care. Roche Holding Ltd. led the Series C round, which also included Allen & Co., Baillie Gifford and Casdin Capital. The New York company raised a $130 million Series B round led by GV, formerly Google Ventures, in 2014.
TangoMe Inc., the company that operates the mobile-messaging service Tango, has named a new chief executive officer months after laying off 9% of its employees. The Mountain View, Calif., company said co-founder Eric Setton, who has been the company’s chief technology officer will succeed Tango co-founder Uri Raz, who becomes executive chairman.
Aver Inc., whose big-data platform is meant to simplify the reimbursement of medical claims by health-insurance companies, has raised $13.6 million in Series B funding. Heritage Group led the round that included Cardinal Health Inc.CAH -2.57%, GE Ventures GE -4.23%, Hearst Health Ventures, and affiliates of NCT Ventures and StartUp Health.
Gem, a blockchain startup, has raised $7 million in Series A funding. Pelion Venture Partners led the round that included Blockchain Capital, Digital Currency Group, KEC Ventures and RRE Ventures.
Welcome to a Medical Battery specialist of the Fluke Battery
Guardant Health Inc. has collected nearly $100 million to expand a service using genomic sequencing to help identify the best therapies for individual patients, Brian Gormley reports for Dow Jones VentureWire. The funding comes amid a push to use genetics to enable personalized cancer treatments. Guardant sequences DNA that tumor cells release into the blood. This can lead oncologists to select a genetically targeted therapy that is likely to work for a particular patient with advanced cancer. OrbiMed Advisors led the Series D round, which adds to the nearly $100 million Guardant raised previously. Existing backers Formation 8, Heritage Group, Khosla Ventures, Lightspeed Venture Partners, Pejman Mar and Sequoia Capital also participated.
Sisense Inc. has raised $50 million for technology that speeds and simplifies the analysis of large, complex data sets so that businesses can make faster decisions. The Series D round was led by Bessemer Venture Partners and included Battery with such as Fluke TiXB Battery, Fluke Ti9 Battery, Fluke TiRX Battery, Fluke TiS Battery, Fluke 215C Battery, Fluke 19XC Battery, Fluke 2X5C Battery, Fluke 435 Battery, Fluke 225C Battery, Contec ECG-1200 Battery, Edan SE-1200 Battery, Contec ECG-1200 BatteryVentures, Draper Fisher Jurvetson, Genesis Partners and Opus Capital.
Sierra Ventures has closed a $170 million fund. San Mateo, Calif.-based Sierra, which made its name with early bets on Intuit INTU -1.61%and Teradata, said it would use the funds to invest in early-stage consumer and enterprise software, as well as connected devices.
C4 Therapeutics Inc. has launched with $73 million in Series A financing and a plan to use a “shock and awe” approach to battling proteins involved in cancer and other diseases. Cobro Ventures led the Series A round, which also included Cormorant Asset Management, EG Capital Group, Kraft Group, Novartis AGNOVN.VX -1.28% and Roche Holding Ltd.
Flatiron Health Inc. has raised $175 million more from corporate and financial investors to expand a cloud-based platform designed to improve cancer care. Roche Holding Ltd. led the Series C round, which also included Allen & Co., Baillie Gifford and Casdin Capital. The New York company raised a $130 million Series B round led by GV, formerly Google Ventures, in 2014.
TangoMe Inc., the company that operates the mobile-messaging service Tango, has named a new chief executive officer months after laying off 9% of its employees. The Mountain View, Calif., company said co-founder Eric Setton, who has been the company’s chief technology officer will succeed Tango co-founder Uri Raz, who becomes executive chairman.
Aver Inc., whose big-data platform is meant to simplify the reimbursement of medical claims by health-insurance companies, has raised $13.6 million in Series B funding. Heritage Group led the round that included Cardinal Health Inc.CAH -2.57%, GE Ventures GE -4.23%, Hearst Health Ventures, and affiliates of NCT Ventures and StartUp Health.
Gem, a blockchain startup, has raised $7 million in Series A funding. Pelion Venture Partners led the round that included Blockchain Capital, Digital Currency Group, KEC Ventures and RRE Ventures.
Venture Capital Dispatch
Venture Capital Dispatch
Welcome to a Medical Battery specialist of the Fluke Battery
Guardant Health Inc. has collected nearly $100 million to expand a service using genomic sequencing to help identify the best therapies for individual patients, Brian Gormley reports for Dow Jones VentureWire. The funding comes amid a push to use genetics to enable personalized cancer treatments. Guardant sequences DNA that tumor cells release into the blood. This can lead oncologists to select a genetically targeted therapy that is likely to work for a particular patient with advanced cancer. OrbiMed Advisors led the Series D round, which adds to the nearly $100 million Guardant raised previously. Existing backers Formation 8, Heritage Group, Khosla Ventures, Lightspeed Venture Partners, Pejman Mar and Sequoia Capital also participated.
Sisense Inc. has raised $50 million for technology that speeds and simplifies the analysis of large, complex data sets so that businesses can make faster decisions. The Series D round was led by Bessemer Venture Partners and included Battery with such as Fluke TiXB Battery, Fluke Ti9 Battery, Fluke TiRX Battery, Fluke TiS Battery, Fluke 215C Battery, Fluke 19XC Battery, Fluke 2X5C Battery, Fluke 435 Battery, Fluke 225C Battery, Contec ECG-1200 Battery, Edan SE-1200 Battery, Contec ECG-1200 BatteryVentures, Draper Fisher Jurvetson, Genesis Partners and Opus Capital.
Sierra Ventures has closed a $170 million fund. San Mateo, Calif.-based Sierra, which made its name with early bets on Intuit INTU -1.61%and Teradata, said it would use the funds to invest in early-stage consumer and enterprise software, as well as connected devices.
C4 Therapeutics Inc. has launched with $73 million in Series A financing and a plan to use a “shock and awe” approach to battling proteins involved in cancer and other diseases. Cobro Ventures led the Series A round, which also included Cormorant Asset Management, EG Capital Group, Kraft Group, Novartis AGNOVN.VX -1.28% and Roche Holding Ltd.
Flatiron Health Inc. has raised $175 million more from corporate and financial investors to expand a cloud-based platform designed to improve cancer care. Roche Holding Ltd. led the Series C round, which also included Allen & Co., Baillie Gifford and Casdin Capital. The New York company raised a $130 million Series B round led by GV, formerly Google Ventures, in 2014.
TangoMe Inc., the company that operates the mobile-messaging service Tango, has named a new chief executive officer months after laying off 9% of its employees. The Mountain View, Calif., company said co-founder Eric Setton, who has been the company’s chief technology officer will succeed Tango co-founder Uri Raz, who becomes executive chairman.
Aver Inc., whose big-data platform is meant to simplify the reimbursement of medical claims by health-insurance companies, has raised $13.6 million in Series B funding. Heritage Group led the round that included Cardinal Health Inc.CAH -2.57%, GE Ventures GE -4.23%, Hearst Health Ventures, and affiliates of NCT Ventures and StartUp Health.
Gem, a blockchain startup, has raised $7 million in Series A funding. Pelion Venture Partners led the round that included Blockchain Capital, Digital Currency Group, KEC Ventures and RRE Ventures.
Welcome to a Medical Battery specialist of the Fluke Battery
Guardant Health Inc. has collected nearly $100 million to expand a service using genomic sequencing to help identify the best therapies for individual patients, Brian Gormley reports for Dow Jones VentureWire. The funding comes amid a push to use genetics to enable personalized cancer treatments. Guardant sequences DNA that tumor cells release into the blood. This can lead oncologists to select a genetically targeted therapy that is likely to work for a particular patient with advanced cancer. OrbiMed Advisors led the Series D round, which adds to the nearly $100 million Guardant raised previously. Existing backers Formation 8, Heritage Group, Khosla Ventures, Lightspeed Venture Partners, Pejman Mar and Sequoia Capital also participated.
Sisense Inc. has raised $50 million for technology that speeds and simplifies the analysis of large, complex data sets so that businesses can make faster decisions. The Series D round was led by Bessemer Venture Partners and included Battery with such as Fluke TiXB Battery, Fluke Ti9 Battery, Fluke TiRX Battery, Fluke TiS Battery, Fluke 215C Battery, Fluke 19XC Battery, Fluke 2X5C Battery, Fluke 435 Battery, Fluke 225C Battery, Contec ECG-1200 Battery, Edan SE-1200 Battery, Contec ECG-1200 BatteryVentures, Draper Fisher Jurvetson, Genesis Partners and Opus Capital.
Sierra Ventures has closed a $170 million fund. San Mateo, Calif.-based Sierra, which made its name with early bets on Intuit INTU -1.61%and Teradata, said it would use the funds to invest in early-stage consumer and enterprise software, as well as connected devices.
C4 Therapeutics Inc. has launched with $73 million in Series A financing and a plan to use a “shock and awe” approach to battling proteins involved in cancer and other diseases. Cobro Ventures led the Series A round, which also included Cormorant Asset Management, EG Capital Group, Kraft Group, Novartis AGNOVN.VX -1.28% and Roche Holding Ltd.
Flatiron Health Inc. has raised $175 million more from corporate and financial investors to expand a cloud-based platform designed to improve cancer care. Roche Holding Ltd. led the Series C round, which also included Allen & Co., Baillie Gifford and Casdin Capital. The New York company raised a $130 million Series B round led by GV, formerly Google Ventures, in 2014.
TangoMe Inc., the company that operates the mobile-messaging service Tango, has named a new chief executive officer months after laying off 9% of its employees. The Mountain View, Calif., company said co-founder Eric Setton, who has been the company’s chief technology officer will succeed Tango co-founder Uri Raz, who becomes executive chairman.
Aver Inc., whose big-data platform is meant to simplify the reimbursement of medical claims by health-insurance companies, has raised $13.6 million in Series B funding. Heritage Group led the round that included Cardinal Health Inc.CAH -2.57%, GE Ventures GE -4.23%, Hearst Health Ventures, and affiliates of NCT Ventures and StartUp Health.
Gem, a blockchain startup, has raised $7 million in Series A funding. Pelion Venture Partners led the round that included Blockchain Capital, Digital Currency Group, KEC Ventures and RRE Ventures.
Wednesday, January 6, 2016
Report is available in its catalogue
Report is available in its catalogue
Welcome to a Medical Battery specialist of the Nihon Kohden Battery
The automated external defibrillatormarket is segmented based on product type into two categories - semi-automated and fully automated defibrillators. Based on end-users,the AED market is classified into five categories, namely, hospitals, pre-hospital, public access, alternate care, and home; the market is forecast till 2017.Automated external defibrillators play an important role in saving the lives of sudden cardiac arrest victims.Considering the life-saving potential of AEDs, legislations requiring installation of public accessdefibrillators (PAD) have been passed in the U.S., Japan, and certain European countries.
The global AEDmarket was worth $616million in the year 2012. Increasing incidences of cardiovascular disease with battery such as Nihon Kohden BSM-2353C Battery, Nihon Kohden BSM-2301K Battery, Nihon Kohden BSM-2351C Battery, Nihon Kohden BSM-2303C Battery, Alaris Medicalsystems SIGNATURE 2 Battery, Alaris Medicalsystems 7000 Battery, Alaris Medicalsystems 7100 Battery, Alaris Medicalsystems 7130 Battery, Alaris Medicalsystems 7200 Battery, JMS 7N-1200SCK Battery, growing awareness about the lifesaving potential of AED, increasing installation of public access AEDs, and advancing technologyare accelerating the growth of this market. However, product recalls, and intense competition in mature markets will hamper the growth of this market, to a certain extent.
The market for AED has become very dynamic, with companies in this segment adoptinggrowth strategies of collaborations, agreements, and acquisitions. Untapped emerging markets and home defibrillators represent vast opportunities for key players in this market.
The geographies covered in this study are North America, Europe, Japan, Asia and Rest of the world (RoW). North America is the largest market for AED, followed by Japan and Europe. North America and Japan are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the increasing installation of AEDs and rising prevalence of cardiovascular diseases.
This research report categorizes the global AED market on the basis product typeinto semi-automated and fully automated defibrillators.The report provides exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the AEDmarketis comprehensively analyzed at a granular level by geography (North America, Europe, Japan, Asia, and Rest of the World) to provide in-depth information on the global scenario.
Welcome to a Medical Battery specialist of the Nihon Kohden Battery
The automated external defibrillatormarket is segmented based on product type into two categories - semi-automated and fully automated defibrillators. Based on end-users,the AED market is classified into five categories, namely, hospitals, pre-hospital, public access, alternate care, and home; the market is forecast till 2017.Automated external defibrillators play an important role in saving the lives of sudden cardiac arrest victims.Considering the life-saving potential of AEDs, legislations requiring installation of public accessdefibrillators (PAD) have been passed in the U.S., Japan, and certain European countries.
The global AEDmarket was worth $616million in the year 2012. Increasing incidences of cardiovascular disease with battery such as Nihon Kohden BSM-2353C Battery, Nihon Kohden BSM-2301K Battery, Nihon Kohden BSM-2351C Battery, Nihon Kohden BSM-2303C Battery, Alaris Medicalsystems SIGNATURE 2 Battery, Alaris Medicalsystems 7000 Battery, Alaris Medicalsystems 7100 Battery, Alaris Medicalsystems 7130 Battery, Alaris Medicalsystems 7200 Battery, JMS 7N-1200SCK Battery, growing awareness about the lifesaving potential of AED, increasing installation of public access AEDs, and advancing technologyare accelerating the growth of this market. However, product recalls, and intense competition in mature markets will hamper the growth of this market, to a certain extent.
The market for AED has become very dynamic, with companies in this segment adoptinggrowth strategies of collaborations, agreements, and acquisitions. Untapped emerging markets and home defibrillators represent vast opportunities for key players in this market.
The geographies covered in this study are North America, Europe, Japan, Asia and Rest of the world (RoW). North America is the largest market for AED, followed by Japan and Europe. North America and Japan are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the increasing installation of AEDs and rising prevalence of cardiovascular diseases.
This research report categorizes the global AED market on the basis product typeinto semi-automated and fully automated defibrillators.The report provides exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the AEDmarketis comprehensively analyzed at a granular level by geography (North America, Europe, Japan, Asia, and Rest of the World) to provide in-depth information on the global scenario.
Subscribe to:
Posts (Atom)